1. Introduction {#s0005}
===============

Abscesses are very common. For example, in the United States alone, 3.2 million people were treated in hospital emergency departments for an abscess infection in 2005 ([@bb0145]). Cutaneous abscesses, triggered by local bacterial infections, are characterized by an accumulation of fluid/pus within the dermis, which is often associated with severe inflammation and induration and frequently lead to a skin lesion that may present as an open sore ([@bb0130]). Severe abscesses that display signs of septic infection are not only surgically drained, but also treated with antibiotics to prevent dissemination, although recurrence can occur ([@bb0130]). An example of a bacterium that often causes abscesses is Methicillin-resistant *Staphylococcus aureus* (MRSA). In addition to its role as an important nosocomial human pathogen, MRSA infections are now emerging in the community as an important cause of skin and soft-tissue infections, many of which are cutaneous abscesses ([@bb0110]). Common antibiotic therapies for MRSA abscesses include trimethoprim-sulfamethoxazole, clindamycin and tetracyclines ([@bb0130], [@bb0150]). However, conditions within the abscess such as low pH, excessive debris and high bacterial loads, as well as low redox potential, have been shown to limit the penetration and efficacy of antibiotics ([@bb0140]). Thus antibiotics work poorly against abscess infections and the substantial consumption of antibiotics over the past decades has resulted in strains that are resistant to virtually all of the utilized antibiotic treatments ([@bb0110], [@bb0130], [@bb0150]). Cutaneous abscesses can also be caused by a variety of other Gram-negative ([@bb0025]) and Gram-positive bacteria ([@bb0100]) making broad spectrum treatments more desirable.

Here we hypothesized that abscesses represent a distinct stress-triggered growth state that make them both resistant to treatment and able to cause pathology. In particular, we have considered the involvement of the universal stringent stress response. The stringent response is a conserved stress response employed by various bacteria to respond to and cope with conditions of amino-acid starvation, carbon-source, fatty acid, oxygen or iron limitation, heat shock, antimicrobial challenge, and/or other environmental stressors ([@bb0030], [@bb0125]). In most bacteria, the stringent response is signaled by the secondary-messenger guanosine tetraphosphate (ppGpp), which serves as a pleiotropic transcriptional regulator by binding to RNA polymerase ([@bb0035]). This leads to the repression of resource-consuming processes (translation, lipid, and cell wall biosynthesis, and to some extent replication and transcription) and diverts resources toward biosynthesis (amino acid biosynthesis and transport, glycolysis) and diverse stress genes to promote survival ([@bb0125], [@bb0135], [@bb0175]).

Cationic amphipathic peptides are an evolutionarily conserved, multifunctional component of the innate immune system. They are known to have immunomodulatory, direct antimicrobial, and/or anti-biofilm activity ([@bb0075]). Importantly, a distinct subset of cationic peptides have demonstrated broad-spectrum efficacy in targeting recalcitrant biofilm infections by targeting the stringent stress response ([@bb0050], [@bb0055], [@bb0120]). Biofilms are a distinct growth state of bacteria on surfaces whereby the bacteria form structured aggregates that are adaptively multi-antibiotic resistant ([@bb0050], [@bb0055], [@bb0115]). The stringent response and biofilm formation are tightly interconnected processes since ppGpp is required for biofilm initiation and maintenance, such that bacterial mutants defective in the stringent response do not form biofilms ([@bb0005], [@bb0050], [@bb0085]). In *S. aureus*, upon amino acid starvation, ppGpp (and its precursor pppGpp) production is mediated by the bi-functional synthase/hydrolase enzyme RSH (a RelA/SpoT homolog) ([@bb0065]).

The ppGpp regulon is very complex ([@bb0155]). For example, in *Escherichia coli*, ppGpp mediates the induction of other stress regulators within the universal stress protein (USP) family ([@bb0095]). Likewise, in *S. aureus*, a homolog, the universal stress protein (designated Usp2) was recently identified and shown to be necessary for persistence under amino acid starvation ([@bb0010]) and is positively regulated by ppGpp ([@bb0065]). Despite these findings, the importance of these stringent response regulators in *S. aureus* pathogenesis remains an understudied topic.

Here we have demonstrated a contribution of the stringent response to *S. aureus* cutaneous abscess formation (as judged by lesion formation and other altered pathology findings), but not local bacterial growth, and demonstrated that it can be targeted pharmacologically with a peptide. Furthermore, the same pharmacological targeting worked with *P. aeruginosa* infections in a cutaneous abscess model.

2. Materials and Methods {#s0010}
========================

2.1. Strains {#s0015}
------------

*S. aureus* wild-type HG001, RSH synthase mutant (*rsh*~syn~) and complemented RSH synthase strain were kindly provided by Christiane Wolz (University of Tübingen, Tübingen). *S. aureus* Newman and Δ*usp2* were provided by Eric Skaar (Vanderbilt University Medical Center, Nashville, TN). Flow cell analysis was conducted on biofilm forming MRSA strain SAP0017 (clinical isolate kindly provided by Dr. Tony Chow, Vancouver General Hospital). For in vivo peptide studies, bioluminescent *S. aureus* USA300 was used and kindly provided by Scott Stibitz (Food and Drug Administration, Silver Spring, MD) and *P. aeruginosa* LESB58 (Liverpool epidemic strain) was from Winstanley et al. ([@bb0170]). All strains in Table S1 were kindly provided by Michael Otto (National Institute of Health, Bethesda, MD).

2.2. Peptide Synthesis {#s0020}
----------------------

DJK-5 (VQWRAIRVRVIR-NH~2~; all D amino acids) was synthesized by CPC Scientific and control peptide IDR-2013 (WQRVRRVKVIRK-NH~2~) was synthesized by Genscript using solid-phase 9-flurenylmethoxy carbonyl (Fmoc) chemistry and purified to \> 95% purity using reverse-phase high-performance liquid chromatography (HPLC). The lyophilized peptide was initially resuspended in endotoxin-free water and used in vitro, or further resuspended in saline and used in vivo.

2.3. Drug Susceptibility Test {#s0025}
-----------------------------

The broth microdilution method with minor modifications for cationic peptides ([@bb0165]) was used for measuring the MIC of peptide DJK-5.

2.4. Flow Cell Analysis {#s0030}
-----------------------

A flow cell system was initially assembled and sterilized as previously described ([@bb0050]). BM2 biofilm-adjusted medium \[62 mM potassium phosphate buffer (pH 7), 7 mM (NH4)~2~SO~4~, 2 mM MgSO~4~, 10 μM FeSO~4~, 0.4% (wt/vol) glucose\] was allowed to pump through the flow cell apparatus for 1 h before the chambers were injected with 1/20 dilutions of overnight culture and bacteria allowed to adhere to the plastic surface of the flow cells for 3 h. To assess the activity of the peptide on pre-formed biofilms, peptide was added to the system two days after the initial bacterial injection and pumped through the system for a subsequent 24 h. Three days following the injection, the flow cells were injected with SYTO-9 and propidium iodide stain \[LIVE/DEAD BacLight Bacterial Viability kit (Molecular Probes, Eugene, OR)\] to image total and dead cells respectively. Remaining biomass was assessed using a confocal laser scanning microscope (Olympus, Fluoview FV1000) and three-dimensional reconstructions were generated using the Imaris software package (Bitplane AG).

2.5. Mouse Skin Infection Model {#s0035}
-------------------------------

Female CD-1 mice (6 weeks old) were purchased from Charles River Laboratories (Wilmington, MA) and were used for the abscess model. Mice were housed together (maximum five/cage) and bedding (shredded paper) and nestlets were provided in each cage. All animal experiments were performed in accordance with The Canadian Council on Animal Care (CCAC) guidelines and were approved by the University of British Columbia Animal Care Committee. The fur on the backs of the mice was removed through shaving and depilatory cream. All *S. aureus* strains were grown to an optical density at 600 nm (OD~600~) of 1 in tryptic soy broth (TSB), while *P. aeruginosa* LESB58 was grown in double yeast tryptone (dYT) medium to an OD~600~ of 1; subsequently cells were washed twice with sterile PBS, and resuspended to a final concentration of 5 × 10^7^ CFU / 50 μL. For mutant studies, bacteria were injected into the right flank of the back. For peptide intraperitoneal (IP) administration studies, mice were initially given either saline or 6 mg/kg DJK-5 (for MRSA studies) or 4 mg/kg DJK-5 (for *P. aeruginosa* studies) in saline via IP injection immediately before applying 50 μL of bacteria subcutaneously to the right flank of the back. For intra-abscess studies, mice received 50 μL of bacteria and 1 h later, 3 mg/kg of peptide via intra-abscess injection. Abscess lesion sizes were measured using a caliper every 24 h for a maximum of 5 days. Visible dermonecrosis or white lesions (filled with pus) were considered as part of the abscess lesion. Swelling/inflammation was however disregarded in the measurements. Mice were monitored once daily and no adverse outcomes were reported. To assess the levels of luminescent bacteria in the abscess every 24 h, the in vivo imaging System (IVIS) (Perkin Elmer, Waltham MA) was utilized. Skin abscesses were excised either two, three or five days post-infection, homogenized using a rotor stator for 5 min and serially diluted for CFU quantification. Furthermore, skin explants were fixed in 10% neutral buffered formalin and processed for hematoxylin and eosin and Gram staining using a Wax it kit (University of British Columbia).

2.6. Evaluation of Histological Slides {#s0040}
--------------------------------------

Histological and Gram stained slides were independently evaluated blindly by veterinarian Dr. Ian Welch at the Centre for Comparative Medicine (Vancouver, Canada) and pathologist Dr. Hamid Masoudi at Vancouver Coastal Health (Vancouver, Canada). All slides used for this independent evaluation are available from the authors upon request with one being presented in Results.

2.7. Measurement of Phenol Soluble Modulins (PSM) {#s0045}
-------------------------------------------------

For luminescent reporter studies, the USA300 PSMα luminescence reporter strain ([@bb0040]) was grown in TSB in the presence of 2.5 or 5 μg/mL DJK-5 or water as a control. Luminescence activity was read for up to 8 h using a VICTORX3 Multilabel Plate reader. Alternatively, USA300 was grown in TSB medium for 8 h at 37 °C at 200 rpm in the presence of sub-lethal concentrations of DJK-5 (1 μg/mL) or water as a control. PSM production in culture filtrates was assessed using HPLC/MS as previously described ([@bb0090]).

2.8. Statistical Evaluation {#s0050}
---------------------------

For bacterial mutant studies, two independent experiments were conducted and data was statistically analyzed using one-way ANOVA or *t*-test. For peptide studies, three independent experiments were conducted and t-tests were used for statistical evaluation. For all animal experiments, the number of biological replicates is indicated in the figure legend. All other experiments were conducted using three biological replicates and evaluated using t-test.

3. Results {#s0055}
==========

3.1. The stringent response was crucial for cutaneous abscess lesion formation in mice {#s1260}
--------------------------------------------------------------------------------------

We first hypothesized that bacteria found within a cutaneous abscess are under significant stress due to limited nutrients and oxygen as well as phagocyte-generated oxidative stress. Therefore, we examined the importance of the bacterial stringent response in a murine cutaneous abscess infection model. To study this, we compared in vivo the lesion-forming ability of *S. aureus* HG001 with that of a mutant defective in RSH synthase (*rsh*~syn~) and thus ppGpp production. The RSH-hydrolase domain is essential for preventing toxic accumulation of ppGpp, such that only RSH mutants defective in the synthase domain are viable ([@bb0060]). Our data showed that the *rsh*~syn~ mutant was severely deficient in abscess lesion formation (13.2 fold smaller lesions compared to the wild type) and genetic complementation of *rsh*~syn~ restored the ability to form abscess lesions ([Fig. 1](#f0005){ref-type="fig"}a). Interestingly, similar viable bacterial counts were recovered from all infected groups ([Fig. 1](#f0005){ref-type="fig"}b), indicating that the stringent response was required for the formation of lesions but not local bacterial growth. Moreover, mice injected with the *rsh-*deficient mutant lost 3.3 fold less weight when compared to the wildtype ([Fig. 1](#f0005){ref-type="fig"}c). Mice infected with *P. aeruginosa* stringent response mutants also formed significantly smaller lesions as compared to wildtype controls (data not shown). Overall, our data indicates that the protective stringent response is critical for cutaneous abscess pathology.

3.2. The universal stress protein (Usp2) was involved in cutaneous lesion and biofilm formation {#s1060}
-----------------------------------------------------------------------------------------------

Based on the interaction of ppGpp with other stress response regulators, we investigated whether Usp2 was also important for cutaneous abscess infections. Mice infected subcutaneously with a *usp2* mutant (Δ*usp2*) demonstrated approximately 2.5 fold smaller abscess lesions compared to those infected with wild-type *S. aureus* Newman ([Fig. 1](#f0005){ref-type="fig"}d); a trend that was not attributed to a growth defect ([Fig. 1](#f0005){ref-type="fig"}e).

Due to the role of ppGpp in stress adaptation and biofilm formation, we investigated the biofilm-forming capacity of ∆* usp2*, which had not been studied to date. Using a flow cell apparatus, imaged by confocal microscopy for live and dead biofilm mass after 3 days of growth, it was determined that ∆* usp2* was severely deficient in biofilm formation ([Fig. 1](#f0005){ref-type="fig"}f). These data collectively provided evidence that both tissue injury and biofilm formation involve induction of the universal stress protein Usp2.

3.3. A Stringent-Response Targeted Peptide, DJK-5, Strongly Reduced *S. aureus* Lesion Formation {#s0060}
------------------------------------------------------------------------------------------------

Synthetic peptides derived from naturally-occurring antimicrobial peptides target the stringent response alarmone ppGpp as the basis for their antibiofilm activity ([@bb0050], [@bb0055]). In particular, [d]{.smallcaps}-enantiomeric peptide, DJK-5, a peptide whose sequence was conceptually based on innate defense regulator (IDR)-1018, impairs bacterial biofilm formation and eradicates preformed biofilms by directly interacting with ppGpp and triggering its degradation ([@bb0055]). It is worth noting that biofilm and abscess infections are generally considered to be quite distinct, although the above data indicated mechanistic overlap.

DJK-5 exhibited very modest antimicrobial activity toward *S. aureus* under planktonic growth conditions, with minimal inhibitory concentrations (MICs) against a variety of strains ranging from 16 to 64 μg/mL (Table S1). In contrast, DJK-5 displayed potent antibiofilm activity, eradicating pre-formed MRSA biofilms at only 2.5 μg/mL (Fig. S1).

Given the activity of DJK-5 against the stringent response and the observed mechanistic overlap between abscess and biofilm formation, we predicted that pharmacological targeting of the stringent response would impact on lesion formation in vivo. When administered via intraperitoneal (IP) injection, DJK-5 dramatically reduced the severity of abscesses formed by the CA-MRSA strain, USA300, by visibly reducing tissue injury and dermonecrosis ([Fig. 2](#f0010){ref-type="fig"}a) as well as significantly reducing lesion size by \> 4.4-fold compared to controls ([Fig. 2](#f0010){ref-type="fig"}b).

Using bioluminescent bacteria in this model allowed for the daily monitoring of bacteria in vivo. After 3 days post-infection, a drop in photon flux was observed in the DJK-5-treated mice when compared to the untreated, infected controls ([Fig. 2](#f0010){ref-type="fig"}c). In previous peptide tracking studies, 2 mg/kg of ^3^H--radiolabelled peptide injected intraperitoneally reached steady-state concentrations of 2--6 μg of peptide per gram of tissue (equivalent to 2--3 μg/mL in the blood) ([@bb0020]). Based on this biodistribution data, we predicted that the dose used in this experiment would not reach MIC levels (32 μg/mL) in the tissues or blood. Consistent with this, despite a 10.2-fold reduction in viable bacteria recovered from the infected site in the DJK-5-treated vs. untreated mice ([Fig. 2](#f0010){ref-type="fig"}d), there was still a significant bacterial load recovered from DJK-5-treated wounds.

These results motivated us to apply the peptide more directly via intra-abscess injection, since direct application into the abscess reflects a potentially more clinically relevant approach. In mice given DJK-5, there was a substantially lower (4.6-fold smaller) lesion size ([Fig. 3](#f0015){ref-type="fig"}a) and 8.4-fold fewer bacteria were recovered from the abscess site ([Fig. 3](#f0015){ref-type="fig"}b). In addition, mice receiving saline lost weight (average 0.3 g weight loss) while mice receiving DJK-5 gained weight ([Fig. 3](#f0015){ref-type="fig"}c), indicating that DJK-5 improved the overall welfare of the mice. We did not observe an improvement in abscess severity or a reduction in abscess size in mice treated with control peptide IDR-2013, a peptide with no anti-biofilm activity against MRSA ([@bb0080]) (Fig. S2). Furthermore, based on independent qualitative observations by two trained pathologists, Gram staining conducted on abscess explants demonstrated that mice treated with DJK-5 exhibited decreased bacterial burden and dissemination within the dermis compared to their saline-treated counterparts ([Fig. 3](#f0015){ref-type="fig"}d). Furthermore, Hematoxylin and Eosin (H&E) staining of abscess explants demonstrated greater tissue damage in saline-treated mice (Table S2; cutaneous ulceration and granulation thickness of 0.9 ± 0.3 cm), as compared to peptide-treated mice (0.2 ± 0.07 cm), with damage extending to the deep fascia of skeletal muscle in saline control animals ([Fig. 3](#f0015){ref-type="fig"}e and Table S2; pathological findings of panniculus carnosus damage and deep skeletal muscle damage were not observed in peptide treated mice).

3.4. DJK-5 Impaired Abscess Lesion Formation by a Gram-Negative Pathogen {#s0065}
------------------------------------------------------------------------

The above results prompted us to ask whether DJK-5 could exert broad-spectrum anti-abscess activity since its target ppGpp, is conserved among Gram-negative and Gram-positive bacteria ([@bb0055], [@bb0125], [@bb0175]). Therefore, we established a Gram-negative bacterial abscess model in mice infected subcutaneously with the Liverpool epidemic strain of *P. aeruginosa* LESB58 ([@bb0170]) and administered 4 mg/kg of DJK-5 or saline as a control via IP injection. Consistent with the results for *S. aureus*, mice treated with DJK-5 formed significantly (*p* \< 0.05) smaller (2.2-fold) abscess lesions when compared to saline controls ([Fig. 4](#f0020){ref-type="fig"}a). There was no significant effect however on recovered viable bacterial counts with peptide treatment ([Fig. 4](#f0020){ref-type="fig"}b). When DJK-5 was administered via intra-abscess application, it was observed that lesions formed on mice treated with DJK-5 were significantly smaller by 2.7-fold ([Fig. 4](#f0020){ref-type="fig"}c) with 5.7-fold fewer bacteria recovered from DJK-5 treated animals ([Fig. 4](#f0020){ref-type="fig"}d). Taken together, these results show the potential for DJK-5 to reduce abscess pathology from both a Gram-positive and a Gram-negative pathogen.

3.5. DJK-5 Suppressed Major Stringently Regulated Cutaneous Phenol Soluble Modulin Toxins in *S. aureus* {#s0070}
--------------------------------------------------------------------------------------------------------

Strikingly, mice treated with DJK-5 exhibited a significant reduction in tissue damage as well as a 10-fold reduction in bacterial burden within the abscess tissue. Despite the possibility that reduced CFUs could account to some extent for the reduced lesion sizes, since significant bacterial loads remained in DJK5-treated wounds, we hypothesized that the peptide could be suppressing abscess pathology by decreasing the expression of a cutaneous toxin.

The stringently regulated *S. aureus* phenol soluble modulin (PSM) toxins have been shown to be the major virulence factors contributing to abscess lesion formation and deletion of the *psm* locus results in the attenuation of virulence in several disease models ([@bb0015]). Therefore, using a *S. aureus* USA300 luminescent reporter strain, we measured the expression of the *psm*α operon when subjected to DJK-5. In order to ensure bacterial growth was not affecting PSM production, sub-lethal concentrations of DJK-5 were employed (Fig. S3). An increasing reduction in *psm*α expression was observed with increasing concentrations of DJK-5 ([Fig. 5](#f0025){ref-type="fig"}a). We further analyzed PSM production by assessing the culture filtrates of peptide-treated USA300. Using a HPLC/MS-based approach ([@bb0090]) it was found that the production of PSMα peptides was generally reduced by DJK-5, with values for PSMα 1 and 2 reaching statistical significance ([Fig. 5](#f0025){ref-type="fig"}b). These results indicate that by targeting the stress response, DJK-5 can suppress phenol soluble modulins, which are known to be implicated in SSTI virulence.

4. Discussion {#s0075}
=============

Bacteria are highly adaptive, dynamic organisms that use a variety of sensor systems to monitor and adapt to environmental conditions ([@bb0125]). Here we showed that stringent stress adaption is a critical determinant of *S. aureus* cutaneous abscess lesion formation. The stringent response has been shown to mediate tolerance of *S. aureus* to cell wall-active antibiotics ([@bb0070]) and we propose that this adaptation is in part responsible for the limited success of conventional antibiotics against bacteria in abscesses. Specifically, our data showed that mutants deficient in either of the two important stringent response mediators (RSH or Usp2), were impaired in lesion formation. Previous studies were somewhat ambiguous since although an *rsh*~syn~ mutant formed fewer kidney abscesses in a murine renal abscess model ([@bb0060]), this observation was proposed to reflect the lower viability (recovery of bacteria) of the *rsh*~syn~ mutant compared to the wild type in the kidneys. In contrast, in the cutaneous abscess model, the very substantial attenuation of abscess lesion formation by the *rsh*~syn~ mutant occurred despite similar levels of bacteria as the wild type, demonstrating a direct contribution of the stringent response. Consistent with this observation, by targeting the stringent response, DJK-5 was able to suppress tissue injury. Despite the major physiological differences in bacterial abscess and biofilm formation, our studies have revealed a strong mechanistic connection that can be exploited with antibiofilm peptides.

In accordance with these observations, we demonstrated the importance of a newly-identified stress response regulator, Usp*2*, both in Staphylococcal abscess lesion formation, albeit to a lesser extent than for the *rsh*~syn~ mutant, and in biofilm formation. This correlates with recent studies that demonstrated the importance of Usp2 in responding to amino acid starvation ([@bb0010]). Biofilm formation is a survival strategy for bacteria to adapt to hostile environments and although bacteria in abscesses are largely considered to be loosely associated in pus, recent evidence suggests that bacteria isolated from deep tissue abscesses are embedded in biofilm-like matrices ([@bb0105]). Of great importance, recurring abscesses and biofilms are similarly recalcitrant to antibiotic therapy ([@bb0045], [@bb0140]). As such, cationic peptides that display antibiofilm activity, can target multidrug resistant bacteria and are synergistic with conventional antibiotics ([@bb0050], [@bb0055]), represent excellent candidates for the adjunctive treatment of recalcitrant cutaneous abscesses.

Our previous studies indicated that DJK-5, a small cationic peptide comprising of D-amino acids, possessed potent antibiofilm activity against a variety of multi-drug resistant Gram-negative species ([@bb0055]). Furthermore, DJK-5 targets the stress response alarmone ppGpp and enhances survival in two invertebrate *P. aeruginosa* biofilm infection models ([@bb0055]). Here we demonstrated that DJK-5 could suppress *S. aureus* and *P. aeruginosa* cutaneous injury in mice, despite the very different physiological states of biofilm and abscess infections. Also, the bacterial load recovered after use of the peptide employed at 3 mg/kg IP, was similar to that for the commonly used antibiotic clindamycin at 75 mg/kg (data not shown), highlighting its potential as an improved anti-abscess strategy.

The stringent response triggers a complex cascade of transcriptional events to counteract environmental stresses. Given that high bacterial loads were still recovered from DJK-5-treated mice ([Fig. 2](#f0010){ref-type="fig"}d and [3](#f0015){ref-type="fig"}b), we considered that the peptide might be suppressing a toxin and indeed demonstrated here that it suppressed the production of the major cutaneous PSM toxins of *S. aureus*. PSMs are positively regulated by the stringent response ([@bb0065]) and consistent with this, our studies indicated that DJK-5 suppressed PSMα production, likely through stringent response impairment.

PSMs recruit, activate and subsequently lyse neutrophils, the key effectors and first responders against bacterial infections ([@bb0015]). Previous studies have shown that upon uptake of *S. aureus* in neutrophils, the stringent response is elicited resulting in increased PSM synthesis, which contributes to survival after phagocytosis by mediating neutrophil lysis ([@bb0065]). Thus by suppressing PSM production, DJK-5 could potentially reduce local tissue damage as well as impede a major immune evasion method employed by *S. aureus*. Given the 10-fold effect on bacterial load, we also considered the potential importance of effects on quorum sensing. Phenol soluble modulins are under the control of the accessory gene regulator (*agr*) quorum sensing pathway as well as the stringent response. However, studies have shown that production of phenol soluble modulins (especially the virulent α-type which are dysregulated by DJK-5), can be produced in an *agr*-independent manner ([@bb0160]). In fact, during the stringent response, RSH-independent induction of phenol soluble modulins, is not mediated by increased *agr* expression ([@bb0065]), confirming a limited correlation between quorum sensing and phenol soluble modulin production under stringent conditions.

In conclusion, we have uncovered mechanisms driving bacterial abscess lesion formation and provide a therapeutic approach to minimize the severity of skin infections by both Methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa*.
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![The stringent response was critical for *S. aureus* abscess lesion and biofilm formation. (a) Mice were infected subcutaneously with *S. aureus* HG001 wildtype, *rsh*~syn~ and rsh~syn~ complement strains. Lesions were measured 24 h post-infection using a caliper, n = 8--10/group. Statistical significance was determined using one-way ANOVA (\*\*\*\*, *p* \< 0.0001) (b) Bacteria were recovered 48 h post-infection from mouse abscesses infected with *S. aureus* HG001, ∆* rsh*~syn~ and complemented*-rsh*~syn~ and then plated for enumeration, n = 9--10/group. (c) Weight loss/gain of infected mice was assessed by measuring the mouse weights pre-infection and 48 h post-infection, n = 9--10/group (\*, *p* \< 0.05). (d) Mice were infected subcutaneously with *S. aureus* Newman parent strain and its Δ*usp2 mutant*. Lesion formation was measured 24 h post-infection using a caliper, n = 7--9/group. Statistical significance was determined using unpaired t-tests (\*\*, *p* \< 0.01). (e) Bacteria were recovered from Newman- and Δ*usp2*- infected mice abscesses after 48 h and plated for enumeration, n = 7--9/group. (f) Newman and Δ*usp2* biofilms were grown in flow cells. After 72 h, bacteria were stained with Syto-9 (live bacteria stain) and propidium iodide (dead bacteria stain) prior to confocal imaging. The scale bar represents 30 μm in length and each image shows the xy, yz and xz dimensions. Two independent experiments were conducted for both animal studies and flow cell experiment.](gr1){#f0005}

![Intraperitoneal application of DJK-5 impaired MRSA cutaneous lesion formation. (a) Mice were injected with 6 mg/kg of DJK-5 or saline as control via intraperitoneal injection prior to receiving subcutaneous injection with bioluminescent MRSA USA300. Representative images capturing dermonecrotic abscess lesions were taken 72 h post-infection. (b) Lesion sizes were measured three days post-infection using a caliper, n = 24 saline, n = 17 DJK-5. (c) Bioluminescent bacteria were imaged using In Vivo Imaging System (IVIS) and quantified using Living Image® Software, n = 20 saline, n = 17 DJK-5. (d) Five days post-infection, bacteria were recovered from saline or DJK-5 treated animals and plated for enumeration, n = 12 saline, n = 10 DJK-5. Three independent experiments were conducted and all comparisons were made using unpaired *t* tests; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](gr2){#f0010}

![Intra-abscess application of DJK-5 impaired MRSA cutaneous injury. (a) Mice were injected with 3 mg/kg of DJK-5 or saline (control) via intra-abscess injection after subcutaneous infection with MRSA USA300. Abscess lesion sizes were measured using a caliper after 72 h, n = 12/group. (b) Bacterial enumeration from saline and DJK-5 intra-abscess-treated abscesses three days post-infection, n = 8 saline, n = 7 DJK-5. (c) Weight loss/gain of infected mice was assessed by measuring the mouse weights pre-infection and 72 h post-infection n = 12 saline, n = 11 DJK-5. (d) Representative Gram stain of saline and DJK-5 treated skin biopsies. (e) Hematoxylin and eosin stain of skin explants taken from saline and DJK-5 treated mice. Yellow arrows indicate suppurative myositis.](gr3){#f0015}

![DJK-5 suppressed Gram-negative abscess lesion formation. (a) Mice were injected with 4 mg/kg of DJK-5 or saline (control) via intraperitoneal injection prior to subcutaneous infection with *P. aeruginosa* LESB58. Abscess lesion sizes were measured using a caliper after 72 h, n = 11/group. (b) Bacteria were recovered from saline and DJK-5 IP-treated animals and plated for enumeration three days post-infection, n = 11/group. (c) Mice were infected subcutaneously with *P. aeruginosa* LESB58 and then treated 2 h later with 4 mg/kg of DJK-5 via intra-abscess injection. Lesions were measured 72 h post-infection with a caliper, n = 10/group. (d) Bacteria were recovered from saline or DJK-5 intra-abscess treated animals and plated for enumeration, n = 10/group. All comparisons were made using unpaired *t* tests; \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001. All experiments were performed in triplicate.](gr4){#f0020}

![DJK-5 targeted PSM production. (a) MRSA USA300 PSMα luminescence reporter strain was grown in the presence of 2.5 μg/mL, 5 μg/mL DJK-5 or water as a control. Luminescence activity was read using a VICTORX3 Multilabel *Plate reader*. (b) PSM production in culture filtrates of *S. aureus* MRSA USA300 treated with 1 μg/mL of DJK-5 or water as a control. All experiments were done in triplicate and all comparisons were done using unpaired t tests; \*, *p* \< 0.05.](gr5){#f0025}
